Nonetheless, clinical trials have demonstrated that secukinumab, an IL-17A inhibitor that is effective in treating psoriasis and PsA, is associated with the onset or exacerbation of IBD, including Crohn’s disease and ulcerative colitis. This evidence concerns the gene IL17A and psoriasis.